Edward White


FBR Weighs in on Volatile Stocks: Kite Pharma Inc (KITE) and Agile Therapeutics Inc (AGRX)

The biotech-verse was buzzing this week after Kite Pharma Inc (NASDAQ:KITE) submitted an IND application for its pipeline cancer drug that sent shares rising. …

FBR Weighs in on Juno Therapeutics Inc (JUNO) Following Meeting with Management

In a research report released Thursday, FBR analyst Edward White reiterated an Outperform rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a price …

FBR Chimes in on Kite Pharma Inc (KITE) Following Positive ZUMA-1 Pivotal Trial Read-Out

Yesterday, Kite Pharma Inc (NASDAQ:KITE) announced positive top-line interim results from its ZUMA-1 pivotal trial in patients with aggressive Non-Hodgkin’s lymphoma (NHL). At …

FBR Analyst Chimes In On Synthetic Biologics Inc (SYN) Following Positive Phase II FDA Meeting

On Tuesday morning, Synthetic Biologics Inc (NYSEMKT:SYN) made a positive stride with the completion of an End of Phase 2 meeting with the FDA for …

FBR Reiterates Outperform On Synthetic Biologics Inc (SYN) Following Meeting With Management

In a research report issued Friday, FBR analyst Edward White reiterated an Outperform rating on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with a price …

FBR Initiates Outperform Rating on Synthetic Biologics Inc; Sees 485% Upside for the Stock

In a research report released Friday, FBR analyst Edward White initiated coverage on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with an Outperform rating …

FBR Capital Initiates Market Perform on Kite Pharma Inc; Sees 22% Upside for the Stock

In a research report released today, FBR Capital analyst Edward White initiated coverage on shares of Kite Pharma Inc (NASDAQ:KITE) with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts